{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'cigarettes per day / 20) X number of years smoked (e.g., 20 cigarettes per day for 10', 'years, or 10 cigarettes per day for 20 years)] Previous smokers are defined as those', 'who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or', 'cigar use cannot be used to calculate pack-year history.', '7. Severity of COPD symptoms: A score of >10 on the COPD Assessment Test (CAT)', 'at Screening (Visit 1).', '8. Severity of Disease:', 'Participants must demonstrate at Screening:', 'a post-bronchodilator FEV1 <50 % predicted normal', 'OR', 'a post-bronchodilator FEV1 <80 % predicted normal and a documented', 'history of >2 moderate exacerbations or one severe (hospitalized)', 'exacerbation in the previous 12 months', 'Participants must also have a measured post albuterol/salbutamol FEV1/forced vital', 'capacity (FVC) ratio of <0.70 at screening.', 'Note: Percent predicted will be calculated using the European Respiratory Society', 'Global Lung Function Initiative reference equations [Quanjer, 2012].', 'Note: A documented history of a COPD exacerbation (e.g., medical record', 'verification) is a medical record of worsening COPD symptoms that required', 'systemic/oral corticosteroids and/or antibiotics (for a moderate exacerbation) or', 'hospitalization (for a severe exacerbation). Prior use of antibiotics alone does not', 'qualify as an exacerbation history unless the use was associated with treatment of', 'worsening symptoms of COPD, such as increased dyspnoea, sputum volume, or', 'sputum purulence (colour). Participant verbal reports are not acceptable.', '9.', 'Existing COPD maintenance treatment: participant must have been receiving', 'daily maintenance treatment with tiotropium alone (via the Handihaler or Respimat)', 'for their COPD for at least 3 months prior to Screening.', 'Note: Participants taking only as-needed tiotropium are not eligible.', '6.2.', 'Exclusion Criteria', 'Participants are excluded from the study if any of the following criteria apply:', '1. Pregnancy: Women who are pregnant or lactating or are planning on becoming', 'pregnant during the study.', '2. Asthma: Participants with a current diagnosis of asthma. (Participants with a prior', 'history of asthma are eligible if they have a current diagnosis of COPD).', '42']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '3. al-antitrypsin deficiency: Participants with al-antitrypsin deficiency as the', 'underlying cause of COPD.', '4. Other respiratory disorders: Participants with active tuberculosis, lung cancer, and', 'clinically significant: bronchiectasis, sarcoidosis, lung fibrosis, pulmonary', 'hypertension, interstitial lung disease or other active pulmonary diseases.', '5. Lung resection: Participants who have undergone lung volume reduction surgery', 'within the 12 months prior to Screening.', '6. Risk Factors for Pneumonia: immune suppression (e.g. advanced human', 'immunodeficiency virus [HIV] with high viral load and low CD4 count, lupus on', 'immunosuppressants) that in the opinion of the investigator would increase risk of', 'pneumonia or other risk factors for pneumonia (e.g. neurological disorders affecting', \"control of the upper airway, such as Parkinson's Disease, Myasthenia Gravis).\", 'Participants at potentially high risk for pneumonia (e.g. very low body mass index', '[BMI], severely malnourished, or very low FEV1) will only be included at the', 'discretion of the Investigator.', '7. Pneumonia and/or moderate or severe COPD exacerbation that has not resolved', 'at least 14 days prior to Screening and at least 30 days following the last dose of', 'oral/systemic corticosteroids (if applicable).', '8. Respiratory tract infection that has not resolved at least 7 days prior to Screening.', '9. Abnormal Chest x-ray: Chest x-ray (posteroanterior and lateral) reveals evidence of', 'pneumonia or a clinically significant abnormality not believed to be due to the', 'presence of COPD, or another condition that would hinder the ability to detect an', 'infiltrate on chest x-ray (e.g. significant cardiomegaly, pleural effusion or scarring).', 'All participants will have a chest x-ray at Screening Visit 1 (or historical radiograph', 'or computerized tomography [CT] scan obtained within 3 months prior to screening).', 'Note: Participants who have experienced pneumonia and/or moderate or severe', 'COPD exacerbations within 3 months of screening must provide a post', 'pneumonia/exacerbation chest X-ray or have a chest X-ray conducted at Screening.', 'For sites in Germany: If a chest x-ray (or CT scan) within 3 months prior to Screening', '(Visit 1) is not available, approval to conduct a diagnostic chest x-ray will need to be', 'obtained from the Federal Office for Radiation Protection (BfS).', '10. Other diseases/abnormalities: Participants with historical or current evidence of', 'clinically significant cardiovascular, neurological, psychiatric, renal, hepatic,', 'immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin,', 'sensory, endocrine (including uncontrolled diabetes or thyroid disease) or', 'haematological abnormalities that are uncontrolled. Significant is defined as any', 'disease that, in the opinion of the Investigator, would put the safety of the participant', 'at risk through participation, or which would affect the efficacy or safety analysis if', 'the disease/condition exacerbated during the study.', '43']\n\n###\n\n", "completion": "END"}